Score Overview
Explore the 2021 public Archive ranking →
Where Aurinia Pharmaceuticals Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- AUPH
2005: 99.6% · 2021: 89.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 16.42 | — |
1 Year2025-09-29 | $ 11.06 | 48.46% |
5 Years2021-09-29 | $ 22.99 | -28.58% |
10 Years2016-09-29 | $ 2.64 | 6x |
20 Years2006-09-29 | $ 54.12 | -69.66% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 |
|---|---|---|---|---|---|
| Price | $ 16.42 | $ 11.06 | $ 22.99 | $ 2.64 | $ 54.12 |
| Return | — | 48.46% | -28.58% | 6x | -69.66% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 311M | $ 314M | $ 443M |
| 2025 | $ 283M | $ 287M | $ 397M |
| 2024 | $ 235M | $ 5M | $ 358M |
| 2023 | $ 175M | -$ 78M | $ 350M |
| 2022 | $ 134M | -$ 108M | $ 389M |
| 2021 | $ 45M | -$ 180M | $ 466M |
| 2020 | $ 50M | -$ 102M | $ 398M |
| 2019 | -$ 88M | $ 306M | |
| 2018 | $ 463K | -$ 64M | $ 125M |
| 2017 | $ 420K | -$ 70M | $ 173M |
| 2016 | $ 173K | -$ 23M | $ 39M |
| 2015 | $ 235K | -$ 18M | $ 15M |
| 2014 | $ 278K | -$ 16M | $ 32M |
| 2013 | $ 948.56K | -$ 2M | $ 1M |
| 2012 | $ 6M | -$ 9M | $ 184.96K |
| 2011 | $ 927.52K | -$ 2M | $ 5M |
| 2010 | $ 3M | -$ 3M | $ 6M |
| 2009 | $ 4M | -$ 7M | $ 4M |
| 2008 | $ 3M | -$ 15M | $ 21M |
| 2007 | $ 2M | -$ 33M | $ 32M |
| 2006 | $ 3M | -$ 22M | $ 22M |
| 2005 | $ 1M | -$ 29M | $ 45M |
| 2004 | $ 1M | -$ 22M | $ 50M |
| 2003 | $ 7M | -$ 14M | $ 62M |
| 2002 | $ 11M | -$ 365.87K | $ 40M |
| 2001 | $ 5M | -$ 7M | $ 33M |
| 2000 | $ 902.77K | -$ 6M | $ 11M |
| IPO1999 | $ 1M | -$ 1M | $ 2M |
Aurinia Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 50M to $ 283M and net income went from -$ 102M to $ 287M. Revenue increased in every one of those 5 years; net income in every one.
Across Aurinia Pharmaceuticals Inc's full reported history, from 1999 to 2025, revenue grew from $ 1M to $ 283M and net income went from -$ 1M to $ 287M. Revenue increased in 52% of the years measured; net income in 48%.
Aurinia Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.8 out of 10. How the HDB Score is calculated.
Membership
Continue AUPH’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
